Objective: To compare the risk of hospitalization for adults with bipolar I disorder (BPD-I) when treated with lurasidone vs. other atypical antipsychotics (AAPs) as monotherapy.
Despite a relatively low prevalence, schizophrenia is one of the top 15 causes of disability worldwide and among the most expensive mental disorders to treat. Relapse, commonly associated...